Sudan ebolavirus

Last updated

Sudan ebolavirus
Virus classification OOjs UI icon edit-ltr.svg
(unranked): Virus
Realm: Riboviria
Kingdom: Orthornavirae
Phylum: Negarnaviricota
Class: Monjiviricetes
Order: Mononegavirales
Family: Filoviridae
Genus: Ebolavirus
Species:
Sudan ebolavirus
Member virus

Sudan virus (SUDV)

The species Sudan ebolavirus is a virological taxon included in the genus Ebolavirus , family Filoviridae , order Mononegavirales . The species has a single virus member, Sudan virus (SUDV). [1] The members of the species are called Sudan ebolaviruses. [1] It was discovered in 1977 and causes Ebola clinically indistinguishable from the ebola Zaire strain, but is less transmissible than it. Unlike with ebola Zaire there is no vaccine available.

Contents

Nomenclature

The name Sudan ebolavirus is derived from Sudan (the country in which Sudan virus was first discovered) and the taxonomic suffix ebolavirus (which denotes an ebolavirus species). [1]

The species was introduced in 1998 as Sudan Ebola virus. [2] [3] In 2002, the name was changed to Sudan ebolavirus. [4] [5]

A virus of the genus Ebolavirus is a member of the species Sudan ebolavirus if: [1]

Sudan virus (SUDV) is one of six known viruses within the genus Ebolavirus and one of the four that causes Ebola virus disease (EVD) in humans and other primates; it is the sole member of the species Sudan ebolavirus. SUDV is a Select agent, World Health Organization Risk Group 4 Pathogen (requiring Biosafety Level 4-equivalent containment), National Institutes of Health/National Institute of Allergy and Infectious Diseases Category A Priority Pathogen, Centers for Disease Control and Prevention Category A Bioterrorism Agent, and listed as a Biological Agent for Export Control by the Australia Group.[ citation needed ]

The first known outbreak of EVD occurred due to Sudan virus in South Sudan between June and November 1976, infecting 284 people and killing 151, with the first identifiable case on 27 June 1976. [6] [7] [8]

Use of term

Sudan virus (abbreviated SUDV) was first described in 1977. [9] It is the single member of the species Sudan ebolavirus, which is included into the genus Ebolavirus , family Filoviridae , order Mononegavirales . [1] The name Sudan virus is derived from South Sudan (where it was first discovered before South Sudan seceded from Sudan [10] ) and the taxonomic suffix virus.[ citation needed ]

Previous designations

Sudan virus was first introduced as a new "strain" of Ebola virus in 1977. [9] Sudan virus was described as "Ebola haemorrhagic fever" in a 1978 WHO report describing the 1976 Sudan outbreak. [11] In 2000, it received the designation Sudan Ebola virus [12] [13] and in 2002 the name was changed to Sudan ebolavirus. [4] [5] Previous abbreviations for the virus were EBOV-S (for Ebola virus Sudan) and most recently SEBOV (for Sudan Ebola virus or Sudan ebolavirus). The virus received its final designation in 2010, when it was renamed Sudan virus (SUDV). [1]

Virus inclusion criteria

A virus of the species Sudan ebolavirus is a Sudan virus (SUDV) if it has the properties of Sudan ebolaviruses and if its genome diverges from that of the prototype Sudan virus, Sudan virus variant Boniface (SUDV/Bon), by ≤10% at the nucleotide level. [1]

Disease

SUDV is one of four ebolaviruses that causes Ebola virus disease (EVD) in humans (in the literature also often referred to as Ebola hemorrhagic fever, EHF). EVD due to SUDV infection cannot be differentiated from EVD caused by other ebolaviruses by clinical observation alone, which is why the clinical presentation and pathology of infections by all ebolaviruses is presented together on a separate page. The strain is less transmissible than Zaire ebolavirus. [14]

In the past, SUDV has caused the following EVD outbreaks: [15] [16] [ additional citation(s) needed ]

Ebola virus disease (EVD) outbreaks due to Sudan virus (SUDV) infection
YearGeographic locationHuman cases/deaths (case-fatality rate)
1976 Juba, Maridi, Nzara, and Tembura, South Sudan 284/151 (53%)
1979 Nzara, South Sudan 34/22 (65%)
2000–2001 Gulu, Mbarara, and Masindi Districts, Uganda 425/224 (53%)
2004Yambio County, South Sudan 17/7 (41%)
2011 Luweero District, Uganda 1/1 (100%)
2014 Equateur, Congo [17] 0/1 * two strains reported, one Sudan and one Sudan/Zaire Hybrid to 24/08/2014 (0%)
2022-2023 Central and Western Regions, Uganda 164/77 (47%)

Vaccine development

As of 2022, there are six experimental vaccines but only three have advanced to the stage where human clinical trials have begun. [18]

As the Public Health Agency of Canada developed a candidate RVSV vaccine for Sudan ebolavirus. Merck was developing it, but as of 18 October 2022 had discontinued development; Merck's monopolies on rVSV techniques, acquired with funding from GAVI, are not available to others developing rVSV vaccines. [19]

As of 2021 GeoVax was developing MVA-SUDV-VLP, which is a modified vaccinia Ankara virus producing Sudan virus-like particles; early data from their research showed the GeoVax vaccine candidate to be 100% effective at preventing death from the Sudan ebolavirus in animals. [20]

An adenovirus based vaccine previously licensed by GSK was donated to and further developed by the Sabin Vaccine Institute in partnership with the Vaccine Research Center at the US National Institute of Allergy and Infectious Diseases; as of October 2022, it will be offered to contacts of known SDV cases in the 2022 Uganda Ebola outbreak as part of a clinical trial. [18]

Ecology

The ecology of SUDV is currently unclear and no reservoir host has yet been identified. Therefore, it remains unclear how SUDV was repeatedly introduced into human populations. As of 2009, bats have been suspected to harbor the virus because infectious Marburg virus (MARV), a distantly related filovirus, has been isolated from bats, [21] and because traces (but no infectious particles) of the more closely related Ebola virus (EBOV) were found in bats as well. [22]

Molecular biology

SUDV is basically uncharacterized on a molecular level. However, its genomic sequence, and with it the genomic organization and the conservation of individual open reading frames, is similar to that of the other four known ebolaviruses. It is therefore currently assumed that the knowledge obtained for EBOV can be extrapolated to SUDV and that all SUDV proteins behave analogous to those of EBOV.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Marburg virus disease</span> Human viral disease

Marburg virus disease is a viral hemorrhagic fever in human and non-human primates caused by either of the two Marburgviruses: Marburg virus (MARV) and Ravn virus (RAVV). Its clinical symptoms are very similar to those of Ebola virus disease (EVD).

<i>Filoviridae</i> Family of viruses in the order Mononegavirales

Filoviridae is a family of single-stranded negative-sense RNA viruses in the order Mononegavirales. Two members of the family that are commonly known are Ebola virus and Marburg virus. Both viruses, and some of their lesser known relatives, cause severe disease in humans and nonhuman primates in the form of viral hemorrhagic fevers.

<i>Mononegavirales</i> Order of viruses

Mononegavirales is an order of negative-strand RNA viruses which have nonsegmented genomes. Some members that cause human disease in this order include Ebola virus, human respiratory syncytial virus, measles virus, mumps virus, Nipah virus, and rabies virus. Important pathogens of nonhuman animals and plants are also in the group. The order includes eleven virus families: Artoviridae, Bornaviridae, Filoviridae, Lispiviridae, Mymonaviridae, Nyamiviridae, Paramyxoviridae, Pneumoviridae, Rhabdoviridae, Sunviridae, and Xinmoviridae.

<i>Marburgvirus</i> Genus of virus

The genus Marburgvirus is the taxonomic home of Marburg marburgvirus, whose members are the two known marburgviruses, Marburg virus (MARV) and Ravn virus (RAVV). Both viruses cause Marburg virus disease in humans and nonhuman primates, a form of viral hemorrhagic fever. Both are select agents, World Health Organization Risk Group 4 Pathogens, National Institutes of Health/National Institute of Allergy and Infectious Diseases Category A Priority Pathogens, Centers for Disease Control and Prevention Category A Bioterrorism Agents, and are listed as Biological Agents for Export Control by the Australia Group.

<i>Ebolavirus</i> Genus of virus

The genus Ebolavirus is a virological taxon included in the family Filoviridae, order Mononegavirales. The members of this genus are called ebolaviruses, and encode their genome in the form of single-stranded negative-sense RNA. The six known virus species are named for the region where each was originally identified: Bundibugyo ebolavirus, Reston ebolavirus, Sudan ebolavirus, Taï Forest ebolavirus, Zaire ebolavirus, and Bombali ebolavirus. The last is the most recent species to be named and was isolated from Angolan free-tailed bats in Sierra Leone. Each species of the genus Ebolavirus has one member virus, and four of these cause Ebola virus disease (EVD) in humans, a type of hemorrhagic fever having a very high case fatality rate. The Reston virus has caused EVD in other primates. Zaire ebolavirus has the highest mortality rate of the ebolaviruses and is responsible for the largest number of outbreaks of the six known species of the genus, including the 1976 Zaire outbreak and the outbreak with the most deaths (2014).

<span class="mw-page-title-main">Mayinga N'Seka</span> Congolese nurse who died from Ebola in 1976

Mayinga N'Seka was a nurse in Zaïre, now Democratic Republic of the Congo. She died from Ebola virus disease during the 1976 epidemic in Zaïre. She has been incorrectly identified as the index case by several sources, but a World Health Organization commission report on the outbreak lists a man from Yambuku, Mabalo Lokela, as the index case. Lokela, a 44-year-old who had been buying meat in Sudan, died on September 8, 1976, over a month before N'Seka.

The species Lloviu cuevavirus is the taxonomic home of a virus that forms filamentous virion, Lloviu virus (LLOV). The species is included in the genus Cuevavirus. LLOV is a distant relative of the commonly known Ebola virus and Marburg virus.

The species Bundibugyo ebolavirus is the taxonomic home of one virus, Bundibugyo virus (BDBV), that forms filamentous virions and is closely related to the infamous Ebola virus (EBOV). The virus causes severe disease in humans in the form of viral hemorrhagic fever and is a Select agent, World Health Organization Risk Group 4 Pathogen, National Institutes of Health/National Institute of Allergy and Infectious Diseases Category A Priority Pathogen, Centers for Disease Control and Prevention Category A Bioterrorism Agent, and is listed as a Biological Agent for Export Control by the Australia Group.

The species Taï Forest ebolavirus is a virological taxon included in the genus Ebolavirus, family Filoviridae, order Mononegavirales. The species has a single virus member, Taï Forest virus (TAFV). The members of the species are called Taï Forest ebolaviruses.

<span class="mw-page-title-main">Reston virus</span> Species of Ebola virus

Reston virus (RESTV) is one of six known viruses within the genus Ebolavirus. Reston virus causes Ebola virus disease in non-human primates; unlike the other five ebolaviruses, it is not known to cause disease in humans, but has caused asymptomatic infections. Reston virus was first described in 1990 as a new "strain" of Ebola virus (EBOV). It is the single member of the species Reston ebolavirus, which is included into the genus Ebolavirus, family Filoviridae, order Mononegavirales. Reston virus is named after Reston, Virginia, US, where the virus was first discovered.

<span class="mw-page-title-main">Marburg virus</span> Species of filamentous virus responsible for hemorrhagic fever

Marburg virus (MARV) is a hemorrhagic fever virus of the Filoviridae family of viruses and a member of the species Marburg marburgvirus, genus Marburgvirus. It causes Marburg virus disease in primates, a form of viral hemorrhagic fever. The virus is considered to be extremely dangerous. The World Health Organization (WHO) rates it as a Risk Group 4 Pathogen. In the United States, the National Institute of Allergy and Infectious Diseases ranks it as a Category A Priority Pathogen and the Centers for Disease Control and Prevention lists it as a Category A Bioterrorism Agent. It is also listed as a biological agent for export control by the Australia Group.

Ravn virus is a close relative of Marburg virus (MARV). RAVV causes Marburg virus disease in humans and nonhuman primates, a form of viral hemorrhagic fever. RAVV is a Select agent, World Health Organization Risk Group 4 Pathogen, National Institutes of Health/National Institute of Allergy and Infectious Diseases Category A Priority Pathogen, Centers for Disease Control and Prevention Category A Bioterrorism Agent, and listed as a Biological Agent for Export Control by the Australia Group.

<span class="mw-page-title-main">Ebola</span> Viral hemorrhagic fever of humans and other primates caused by ebolaviruses

Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. Symptoms typically start anywhere between two days and three weeks after infection. The first symptoms are usually fever, sore throat, muscle pain, and headaches. These are usually followed by vomiting, diarrhoea, rash and decreased liver and kidney function, at which point some people begin to bleed both internally and externally. It kills between 25% and 90% of those infected – about 50% on average. Death is often due to shock from fluid loss, and typically occurs between six and 16 days after the first symptoms appear. Early treatment of symptoms increases the survival rate considerably compared to late start. An Ebola vaccine was approved by the US FDA in December 2019.

<i>Zaire ebolavirus</i> Species of virus affecting humans and animals

Zaire ebolavirus, more commonly known as Ebola virus, is one of six known species within the genus Ebolavirus. Four of the six known ebolaviruses, including EBOV, cause a severe and often fatal hemorrhagic fever in humans and other mammals, known as Ebola virus disease (EVD). Ebola virus has caused the majority of human deaths from EVD, and was the cause of the 2013–2016 epidemic in western Africa, which resulted in at least 28,646 suspected cases and 11,323 confirmed deaths.

rVSV-ZEBOV vaccine Vaccine against Ebola virus disease

Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-ZEBOV has shown a high level of protection. Around half the people given the vaccine have mild to moderate adverse effects that include headache, fatigue, and muscle pain.

<span class="mw-page-title-main">2014 Democratic Republic of the Congo Ebola virus outbreak</span> Disease outbreak in central Africa

In 2014, an outbreak of Ebola virus disease in the Democratic Republic of the Congo (DRC) occurred. Genome sequencing has shown that this outbreak was not related to the 2014–15 West Africa Ebola virus epidemic, but was of the same EBOV species. It began in August 2014 and was declared over in November of that year, after 42 days without any new cases. This is the 7th outbreak there, three of which occurred during the period of Zaire.

<span class="mw-page-title-main">Ebola vaccine</span> Vaccine against Ebola

Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates against lethal infection.

cAd3-ZEBOV Experimental vaccine for ebolaviruses

cAd3-ZEBOV was an experimental vaccine for two ebolaviruses, Ebola virus and Sudan virus, developed by scientists at GlaxoSmithKline (GSK) and tested by National Institute of Allergy and Infectious Disease (NIAID). This vaccine is derived from a chimpanzee adenovirus, Chimp Adenovirus type 3 (ChAd3), genetically engineered to express glycoproteins from the Zaire and Sudan species of ebolavirus to provoke an immune response against them. Simultaneous phase 1 trials of this vaccine commenced in September 2014, being administered to volunteers in Oxford and Bethesda. During October the vaccine is being administered to a further group of volunteers in Mali. If this phase is completed successfully, the vaccine will be fast tracked for use in the Ebola virus epidemic in West Africa. In preparation for this, GSK is preparing a stockpile of 10,000 doses.

<span class="mw-page-title-main">2018 Équateur province Ebola outbreak</span> Disease outbreak in the Democratic Republic of the Congo

The 2018 Équateur province Ebola outbreak occurred in the north-west of the Democratic Republic of the Congo (DRC) from May to July 2018. It was contained entirely within Équateur province, and was the first time that vaccination with the rVSV-ZEBOV Ebola vaccine had been attempted in the early stages of an Ebola outbreak, with a total of 3,481 people vaccinated. It was the ninth recorded Ebola outbreak in the DRC.

References

  1. 1 2 3 4 5 6 7 Kuhn, Jens H.; Becker, Stephan; Ebihara, Hideki; Geisbert, Thomas W.; Johnson, Karl M.; Kawaoka, Yoshihiro; Lipkin, W. Ian; Negredo, Ana I; et al. (2010). "Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations". Archives of Virology. 155 (12): 2083–103. doi:10.1007/s00705-010-0814-x. PMC   3074192 . PMID   21046175.
  2. ↑ Netesov, S. V.; Feldmann, H.; Jahrling, P. B.; Klenk, H. D.; Sanchez, A. (2000). "Family Filoviridae". In van Regenmortel, M. H. V.; Fauquet, C. M.; Bishop, D. H. L.; Carstens, E. B.; Estes, M. K.; Lemon, S. M.; Maniloff, J.; Mayo, M. A.; McGeoch, D. J.; Pringle, C. R.; Wickner, R. B. (eds.). Virus Taxonomy—Seventh Report of the International Committee on Taxonomy of Viruses. San Diego, USA: Academic Press. pp. 539–48. ISBN   978-0-12-370200-5.
  3. ↑ Pringle, C. R. (1998). "Virus taxonomy-San Diego 1998". Archives of Virology . 143 (7): 1449–59. doi:10.1007/s007050050389. PMID   9742051. S2CID   13229117.
  4. 1 2 Feldmann, H.; Geisbert, T. W.; Jahrling, P. B.; Klenk, H.-D.; Netesov, S. V.; Peters, C. J.; Sanchez, A.; Swanepoel, R.; Volchkov, V. E. (2005). "Family Filoviridae". In Fauquet, C. M.; Mayo, M. A.; Maniloff, J.; Desselberger, U.; Ball, L. A. (eds.). Virus Taxonomy – Eighth Report of the International Committee on Taxonomy of Viruses. San Diego, USA: Elsevier/Academic Press. pp. 645–653. ISBN   978-0-12-370200-5.
  5. 1 2 Mayo, M. A. (2002). "ICTV at the Paris ICV: results of the plenary session and the binomial ballot". Archives of Virology. 147 (11): 2254–60. doi:10.1007/s007050200052. S2CID   43887711.
  6. ↑ "Ebola haemorrhagic fever in Sudan, 1976" (PDF). Archived from the original (PDF) on 13 October 2014.
  7. ↑ Feldmann, H.; Geisbert, T. W. (2011). "Ebola haemorrhagic fever". The Lancet. 377 (9768): 849–862. doi:10.1016/S0140-6736(10)60667-8. PMC   3406178 . PMID   21084112.
  8. ↑ Hoenen T, Groseth A, Feldmann H (July 2012). "Current ebola vaccines". Expert Opin Biol Ther. 12 (7): 859–72. doi:10.1517/14712598.2012.685152. PMC   3422127 . PMID   22559078.
  9. 1 2 Bowen, E. T. W.; Lloyd, G.; Harris, W. J.; Platt, G. S.; Baskerville, A.; Vella, E. E. (1977). "Viral haemorrhagic fever in southern Sudan and northern Zaire, Preliminary studies on the aetiological agent". Lancet. 309 (8011): 571–3. doi:10.1016/s0140-6736(77)92001-3. PMID   65662. S2CID   3092094.
  10. ↑ Nzara, South Sudan
  11. ↑ "Home" (PDF). Archived from the original (PDF) on 13 October 2014. Retrieved 11 February 2015.
  12. ↑ Netesov, S. V.; Feldmann, H.; Jahrling, P. B.; Klenk, H. D.; Sanchez, A. (2000). "Family Filoviridae". In van Regenmortel, M. H. V.; Fauquet, C. M.; Bishop, D. H. L.; Carstens, E. B.; Estes, M. K.; Lemon, S. M.; Maniloff, J.; Mayo, M. A.; McGeoch, D. J.; Pringle, C. R.; Wickner, R. B. (eds.). Virus Taxonomy – Seventh Report of the International Committee on Taxonomy of Viruses. San Diego, USA: Academic Press. pp. 539–48. ISBN   978-0-12-370200-5.
  13. ↑ Pringle, C. R. (1998). "Virus taxonomy-San Diego 1998". Archives of Virology. 143 (7): 1449–59. doi:10.1007/s007050050389. PMID   9742051. S2CID   13229117.
  14. ↑ Biryabarema, Elias (22 September 2022). "Uganda has confirmed seven Ebola cases so far, one death". Reuters. Retrieved 23 September 2022.
  15. ↑ "Ebola outbreak: DR Congo confirms two deaths". BBC. 24 August 2014.
  16. ↑ "Ebola Disease caused by Sudan virus – Uganda". www.who.int. Retrieved 27 September 2022.
  17. ↑ "Ebola outbreak: DR Congo confirms two deaths". BBC. 24 August 2014.
  18. 1 2 Helen Branswell (29 September 2022). "Ebola experimental vaccine trial may begin soon in Uganda". STAT News. Retrieved 10 October 2022.
  19. ↑ "MSF's response to CEPI's policy regarding equitable access". Médecins Sans Frontières Access Campaign. 25 September 2018. Retrieved 23 September 2022. In vaccine development, access to know how is important. Knowledge and expertise including but not limited to purification techniques, cell lines, materials, software codes and their transfer of this to alternative manufacturers in the event the awardee discontinues development of a promising vaccine is critically important. The recent example of Merck abandoning the development of rVSV vaccines for Marburg (rVSV-MARV) and for Sudan-Ebola (rVSV-SUDV) is a case in point. Merck continues to retain vital know-how on the rVSV platform as it developed the rVSV vaccine for Zaire-Ebola (rVSV-ZEBOV) with funding support from GAVI. While it has transferred the rights on these vaccines back to Public Health Agency of Canada, there is no mechanism to share know how on the rVSV platform with other vaccine developers who would like to also use rVSV as a vector against other pathogens.
  20. ↑ "GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting". 21 July 2021.
  21. ↑ Towner, J. S.; Amman, B. R.; Sealy, T. K.; Carroll, S. A. R.; Comer, J. A.; Kemp, A.; Swanepoel, R.; Paddock, C. D.; Balinandi, S.; Khristova, M. L.; Formenty, P. B.; Albarino, C. G.; Miller, D. M.; Reed, Z. D.; Kayiwa, J. T.; Mills, J. N.; Cannon, D. L.; Greer, P. W.; Byaruhanga, E.; Farnon, E. C.; Atimnedi, P.; Okware, S.; Katongole-Mbidde, E.; Downing, R.; Tappero, J. W.; Zaki, S. R.; Ksiazek, T. G.; Nichol, S. T.; Rollin, P. E. (2009). Fouchier, Ron A. M. (ed.). "Isolation of Genetically Diverse Marburg Viruses from Egyptian Fruit Bats". PLOS Pathogens. 5 (7): e1000536. doi: 10.1371/journal.ppat.1000536 . PMC   2713404 . PMID   19649327.
  22. ↑ Leroy, E. M.; Kumulungui, B.; Pourrut, X.; Rouquet, P.; Hassanin, A.; Yaba, P.; Délicat, A.; Paweska, J. T.; Gonzalez, J. P.; Swanepoel, R. (2005). "Fruit bats as reservoirs of Ebola virus". Nature. 438 (7068): 575–576. Bibcode:2005Natur.438..575L. doi:10.1038/438575a. PMID   16319873. S2CID   4403209.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.